There were 1,695 press releases posted in the last 24 hours and 456,324 in the last 365 days.

Melioidosis R&D Pipeline Analysis Report, H2-2018

/EIN News/ -- Dublin, Jan. 28, 2019 (GLOBE NEWSWIRE) -- The "Melioidosis R&D Pipeline Analysis Report, H2-2018" drug pipelines has been added to's offering.

Melioidosis Drug Development Pipeline Study is the latest publication from this researcher with comprehensive information of Melioidosis pipeline products.

The Melioidosis pipeline guide presents complete overview of drugs currently being developed for Melioidosis. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Melioidosis pipeline candidate.
Research and Development progress along with latest news related to each of the Melioidosis pipeline candidates is included.

Major companies participating in therapeutic development of Melioidosis are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Melioidosis from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Melioidosis clinical and pre clinical products.

The report assists in identifying potential upcoming companies and drugs in Melioidosis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Key Topics Covered:

I. Key Findings

1. Companies Investing in Melioidosis Pipeline include
Number of Companies with Melioidosis projects in pre clinical Development
Number of Companies with Melioidosis projects in Clinical Development

2. Pipeline Candidates include
Melioidosis Pipeline Agents in pre clinical/ Discovery stage of Development
Melioidosis Pipeline Agents in Clinical Development stage
Melioidosis Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Melioidosis Pipeline agents

II. Insights into Melioidosis Pipeline -

1. Disease Overview
Introduction to Melioidosis
Symptoms and Causes of Melioidosis
Treatment or Prevention Options for Melioidosis
Other Details
2. Phase wise Pipeline Compounds
Melioidosis Pipeline Pre Clinical/ Discovery stage Drugs
Melioidosis Pipeline Phase 1 stage Drugs
Melioidosis Pipeline Phase 2 stage Drugs
Melioidosis Pipeline Phase 3 stage Drugs
Melioidosis Pipeline Pre Registration stage Drugs
3. Company wise Melioidosis Pipeline Compounds
4. Melioidosis Pipeline by Mechanism of Action

III. Melioidosis Pipeline Compound Details

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Developing Company
Co Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Melioidosis Pipeline Company Briefs

V. Latest News and Developments in Global Melioidosis Pipeline Market

VI. Appendix

For more information about this drug pipelines report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs